fr   en
Agreements
Select a partner :
Type of agreement :





Select a compound/Disease :
Choose date:
[<<]      «      55   |   56   |   57   |   58   |   59   |   60   |   61   |   62   |   63   |   64   |   65      »      [65]
Date Partners Compound / Disease area / Development phase Type of agreement Nature / Financial terms
2006-12-08 Protherics (UK)/Advancell
 
acadesine (nucleoside analogue) / chronic B cell lymphoid leukaemia licensing
development
See details
2006-12-08 Protherics (UK)/Glenveigh (USA)
 
Anti-digoxin polyclonal antibody fragments, including DigiFab® and DigiBind® / pre-eclampsia and eclampsia licensing
See details
2006-12-07 Genentech (USA)/AC Immune (Switzerland)
 
immunotherapy (anti-amyloid protein ß antibodies) / Alzheimer's disease and other human diseases R&D
licensing
See details
2006-12-06 Thrombogenics (Belgium)/Bharat Biotech International (India)
 
THR-100 (recombinant staphylokinase) / myocardial infarction other
See details
2006-12-05 Novexel (France)
Indevus Pharmaceuticals (USA)
aminocandin / severe fungal diseases such as aspergilloses and candidoses licensing
See details
2006-12-04 PanGenetics (The Netherlands)/Lay Line Genomics (Italy)
 
Hu-alpha D11 (humanised antibody against neurotrophic growth factor) / inflammatory pain, neuropathic pain, pain in cancer patients licensing
See details
2006-12-04 Xention (UK)
Scion Pharmaceuticals (USA)
ion channels modulators / overactive bladder syndrome , irritable bowel syndrome and erectile dysfunction. development
See details
2006-11-27 Biota (Australia)
Boehringer Ingelheim (Germany)
nucleoside analogues / hepatitis C commercialization/ distribution
development
See details
2006-11-22 Galapagos/BioFocus DPI (Belgium)
Cystic Fibrosis Foundation Therapeutics (CFFT)
discovery of novel drug targets for the development of new cystic fibrosis therapies / cystic fibrosis R&D
See details
2006-11-20 Bioceuticals (Germany)
Stada (Germany)/Hospira (USA)
erythropoietin zeta /   manufacturing
commercialization/ distribution
development
See details
2006-11-20 Cambridge Antibody Technology (CAT)
Debiopharm (Switzerland)
SC-1 (monoclonal antibody targeting a receptor expressed specifically at the surface of gastric carcinoma cells / stomach cancer, an indication for which the SC-1 has obtained orphan status from the FDA. commercialization/ distribution
development
See details
2006-11-20 GTC Biotherapeutics (USA)/LFB Biotechnologies (France)
 
recombinant plasma proteins and monoclonal antibodies. The first protein on which the two partners will work is a recombinant form of activated factor VII for the treatment of clotting diseases. /   R&D
commercialization/ distribution
See details
2006-11-20 Ablynx (Belgium)
Wyeth (USA)
Nanobodies ® against tumour necrosis factor alpha (TNF-alpha) and its receptors. / undisclosed drug targets R&D
commercialization/ distribution
See details
2006-11-20 Diatos (France)
Medarex (USA)
DTS-201, a doxorubicin prodrug / cancer commercialization/ distribution
See details
2006-11-20 mondoBiotech (Switzerland)
Biogen Idec (USA)
aviptadil / pulmonary arterial hypertension (PAH), an indication for which the compound has orphan status in the EU and the USA. manufacturing
commercialization/ distribution
development
See details
[<<]      «      55   |   56   |   57   |   58   |   59   |   60   |   61   |   62   |   63   |   64   |   65      »      [65]